Sinovac Biotech (SVA) 4.95 $SVA
Sinovac Biotech Shares Down 13.9% Since SmarTrend's Sell Call (SVA)
Comtex SmarTrend(R) - Wed Sep 10, 11:11AM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 5 months, Sinovac Biotech has returned 13.93% as of today's recent price of $5.06.
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
Sinovac Announces New Presentation Time for Aegis Healthcare & Technology Conference
PR Newswire - Fri Sep 05, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced a new presentation time for the Aegis Healthcare & Technology Conference, to be held at the Wynn Las Vegas on September 12, 2014. Management will present at 8:00 am PT.
China Human Vaccine Industry Report, 2014-2017
M2 - Thu Sep 04, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sj5z5x/china_human) has announced the addition of the "China Human Vaccine Industry Report, 2014-2017" report to their offering. Chinese human vaccine market is still dominated by Beijing Tiantan Biological, Chengdu Institute of Biology under Chinese Academy of Sciences, Shanghai Institute of Biological Products Co., Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises; but, their market share is falling. In 2013, the lot release volume of Chinese state-owned enterprises accounted for 69.9%, down 8.6 percentage points compared with last year; whereas, the share of private and foreign-funded enterprises jumped by 6 percentage points and 2.6 percentage points over the previous year respectively. The improved quality of Chinese vaccines, the increased export tax rebates (from 13% in 2009 to 15%) and other favorable factors have prompted China's human vaccine export volume and value to grow quickly. From January to June of 2014, the export volume and value amounted to 65.08 tons and USD15.45 million respectively, representing the separate increase of 115.6% and 50% over the same period of last year. As China's vaccine regulatory system is recognized by WHO, Chengdu Institute of Biology under Chinese Academy of Sciences, Beijing Tiantan Biological, Hualan Biological and other domestic vaccine companies are actively submitting pre-certification application to WHO in order to further expand overseas markets. In October 2013, the JE (Japanese encephalitis) vaccines of Chengdu Institute of Biology under Chinese Academy of Sciences were pre-certified by WHO at first and included in the procurement list of the United Nations. WHO inspected the influenza (split virion) vaccines of Hualan Biological on the spot in April 2014, and these vaccines are expected to be exported in 2015. Key Topics Covered: 1. Overview of Vaccine Industry 2. China Human Vaccine Industry & Market 3. Human Vaccine Market Segments in China 4. China's Import and Export of Vaccines 5. Major Vaccine Manufacturers in China - Beijing Tiantan Biological Products Co., Ltd - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd - Dalian Hissen Bio-Pharm Co., Ltd - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd - Sinovac Biotech Ltd. - Walvax Biotechnology Co., Ltd - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/sj...hina_human
Nasdaq stocks posting largest percentage decreases
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Sinovac Biotech Down 11.7% Since SmarTrend Downtrend Call (SVA)
Comtex SmarTrend(R) - Wed Sep 03, 9:24AM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 5 months, Sinovac Biotech has returned 11.73% as of today's recent price of $5.19.
Sinovac to Participate in Upcoming Investor Conferences
PR Newswire - Tue Sep 02, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will participate in the following investor conferences in September:
Simavita Limited: Release of 2014 Financial Results
Marketwire - Thu Aug 28, 6:51PM CDT
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to release its audited financial results and Management's Discussion and Analysis for the year ended June 30, 2014 available on SEDAR at www.sedar.ca. These year-end financials are the first such document produced by the Company since its re-listing on the TSX-V and its admission to the Official List of the ASX and includes financial information pertaining to its acquisition of Simavita Holdings Limited in December 2013.
Sinovac Announces Results of 2014 Annual General Meeting of Shareholders
PR Newswire - Wed Aug 27, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2014 Annual General Meeting of Shareholders held on Wednesday, August 27, 2014 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy.
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
Sinovac Reports Unaudited Second Quarter Financial Results
PR Newswire - Thu Aug 14, 11:49AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2014.
Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
PR Newswire - Fri Jul 25, 4:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August 14, 2014 EDT. The Company will host a conference call prior to the market opening on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac to supply seasonal flu vaccine Anflu in Beijing in Q3 2014
M2 - Wed Jul 23, 7:07AM CDT
Chinese biopharmaceutical company Sinovac Biotech (NasdaqGS:SVA) said on Wednesday that it will supply the seasonal influenza vaccine Anflu in Beijing, beginning in the third quarter of 2014, following authorisation from Beijing Centers for Disease Control and Prevention (Beijing CDC).
Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu
PR Newswire - Wed Jul 23, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention ("Beijing CDC" to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014.
Monday’s Top Biotech Stories: Allergan, Anacor, and Sinovac Biotech
Leo Sun, The Motley Fool - Motley Fool - Mon Jul 21, 8:06AM CDT
Let's take a look at three stocks -- Allergan , Anacor Pharmaceuticals , and Sinovac Biotech -- which could all loom large in health care headlines this Monday morning. Allergan tops earnings estimates for the second quarter Allergan...
Sinovac wins CNY16m tender to supply inactivated hepatitis A vaccine Healive in Beijing
M2 - Mon Jul 21, 7:34AM CDT
Biopharmaceutical company Sinovac Biotech (NasdaqGS:SVA) reported on Monday that it is the exclusive supplier of inactivated hepatitis A vaccine Healive in pre-filled syringe dosage in Beijing under the Expanded Programme of Immunisation (EPI).
Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program
PR Newswire - Mon Jul 21, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the Expanded Program of Immunization (EPI) for Beijing. The tender is valued at approximately 16 million RMB. The vaccines purchased by the Beijing Health Bureau will be used for the period from 2014 to 2016. The Company expects to begin delivery in the coming months upon the demand.
Sinovac Schedules 2014 Annual Meeting of Shareholders
PR Newswire - Mon Jul 14, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC. All shareholders of record as of July 9, 2014 will be eligible to vote and are invited to attend.
Sinovac Biotech Shares Down 13.9% Since SmarTrend's Sell Call (SVA)
Comtex SmarTrend(R) - Wed Sep 10, 11:11AM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 5 months, Sinovac Biotech has returned 13.93% as of today's recent price of $5.06.
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
Sinovac Announces New Presentation Time for Aegis Healthcare & Technology Conference
PR Newswire - Fri Sep 05, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced a new presentation time for the Aegis Healthcare & Technology Conference, to be held at the Wynn Las Vegas on September 12, 2014. Management will present at 8:00 am PT.
China Human Vaccine Industry Report, 2014-2017
M2 - Thu Sep 04, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sj5z5x/china_human) has announced the addition of the "China Human Vaccine Industry Report, 2014-2017" report to their offering. Chinese human vaccine market is still dominated by Beijing Tiantan Biological, Chengdu Institute of Biology under Chinese Academy of Sciences, Shanghai Institute of Biological Products Co., Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises; but, their market share is falling. In 2013, the lot release volume of Chinese state-owned enterprises accounted for 69.9%, down 8.6 percentage points compared with last year; whereas, the share of private and foreign-funded enterprises jumped by 6 percentage points and 2.6 percentage points over the previous year respectively. The improved quality of Chinese vaccines, the increased export tax rebates (from 13% in 2009 to 15%) and other favorable factors have prompted China's human vaccine export volume and value to grow quickly. From January to June of 2014, the export volume and value amounted to 65.08 tons and USD15.45 million respectively, representing the separate increase of 115.6% and 50% over the same period of last year. As China's vaccine regulatory system is recognized by WHO, Chengdu Institute of Biology under Chinese Academy of Sciences, Beijing Tiantan Biological, Hualan Biological and other domestic vaccine companies are actively submitting pre-certification application to WHO in order to further expand overseas markets. In October 2013, the JE (Japanese encephalitis) vaccines of Chengdu Institute of Biology under Chinese Academy of Sciences were pre-certified by WHO at first and included in the procurement list of the United Nations. WHO inspected the influenza (split virion) vaccines of Hualan Biological on the spot in April 2014, and these vaccines are expected to be exported in 2015. Key Topics Covered: 1. Overview of Vaccine Industry 2. China Human Vaccine Industry & Market 3. Human Vaccine Market Segments in China 4. China's Import and Export of Vaccines 5. Major Vaccine Manufacturers in China - Beijing Tiantan Biological Products Co., Ltd - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd - Dalian Hissen Bio-Pharm Co., Ltd - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd - Sinovac Biotech Ltd. - Walvax Biotechnology Co., Ltd - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/sj...hina_human
Nasdaq stocks posting largest percentage decreases
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Sinovac Biotech Down 11.7% Since SmarTrend Downtrend Call (SVA)
Comtex SmarTrend(R) - Wed Sep 03, 9:24AM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 5 months, Sinovac Biotech has returned 11.73% as of today's recent price of $5.19.
Sinovac to Participate in Upcoming Investor Conferences
PR Newswire - Tue Sep 02, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will participate in the following investor conferences in September:
Simavita Limited: Release of 2014 Financial Results
Marketwire - Thu Aug 28, 6:51PM CDT
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to release its audited financial results and Management's Discussion and Analysis for the year ended June 30, 2014 available on SEDAR at www.sedar.ca. These year-end financials are the first such document produced by the Company since its re-listing on the TSX-V and its admission to the Official List of the ASX and includes financial information pertaining to its acquisition of Simavita Holdings Limited in December 2013. Sinovac Announces Results of 2014 Annual General Meeting of Shareholders
PR Newswire - Wed Aug 27, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2014 Annual General Meeting of Shareholders held on Wednesday, August 27, 2014 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy.
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
Sinovac Reports Unaudited Second Quarter Financial Results
PR Newswire - Thu Aug 14, 11:49AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2014.
Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
PR Newswire - Fri Jul 25, 4:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August 14, 2014 EDT. The Company will host a conference call prior to the market opening on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac to supply seasonal flu vaccine Anflu in Beijing in Q3 2014
M2 - Wed Jul 23, 7:07AM CDT
Chinese biopharmaceutical company Sinovac Biotech (NasdaqGS:SVA) said on Wednesday that it will supply the seasonal influenza vaccine Anflu in Beijing, beginning in the third quarter of 2014, following authorisation from Beijing Centers for Disease Control and Prevention (Beijing CDC).
Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu
PR Newswire - Wed Jul 23, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention ("Beijing CDC"
to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014. Monday’s Top Biotech Stories: Allergan, Anacor, and Sinovac Biotech
Leo Sun, The Motley Fool - Motley Fool - Mon Jul 21, 8:06AM CDT
Let's take a look at three stocks -- Allergan , Anacor Pharmaceuticals , and Sinovac Biotech -- which could all loom large in health care headlines this Monday morning. Allergan tops earnings estimates for the second quarter Allergan...
Sinovac wins CNY16m tender to supply inactivated hepatitis A vaccine Healive in Beijing
M2 - Mon Jul 21, 7:34AM CDT
Biopharmaceutical company Sinovac Biotech (NasdaqGS:SVA) reported on Monday that it is the exclusive supplier of inactivated hepatitis A vaccine Healive in pre-filled syringe dosage in Beijing under the Expanded Programme of Immunisation (EPI).
Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program
PR Newswire - Mon Jul 21, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the Expanded Program of Immunization (EPI) for Beijing. The tender is valued at approximately 16 million RMB. The vaccines purchased by the Beijing Health Bureau will be used for the period from 2014 to 2016. The Company expects to begin delivery in the coming months upon the demand.
Sinovac Schedules 2014 Annual Meeting of Shareholders
PR Newswire - Mon Jul 14, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC. All shareholders of record as of July 9, 2014 will be eligible to vote and are invited to attend.
